Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis

Fig. 1

Patient enrollment flowchart. In all, 62 patients were selected using the propensity score-matched sample from three multicenter, prospective, single-arm, open-label, phase II studies. 5-HT3RA, 5-hydroxytryptamine-3 receptor antagonists; DEX, dexamethasone; OLZ, olanzapine

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us